3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
1
Multiple Myeloma
1
Genetic Diseases, Inborn
1
Interventions
Cisplatin
118
Radiotherapy
114
Cyclophosphamide
93
Paclitaxel
84
Gemcitabine
74
Carboplatin
67
Filgrastim
60
Doxorubicin
57
Vincristine
56
Etoposide
56
Docetaxel
56
Fluorouracil
51
Cytarabine
41
Prednisone
40
Methotrexate
40
Leucovorin
39
Dexamethasone
37
Capecitabine
36
Irinotecan
35
Rituximab
29
Oxaliplatin
28
Granulocyte Colony-Stimulating Factor
27
Cetuximab
26
Bevacizumab
26
durvalumab
24
Temozolomide
24
Radiotherapy, Intensity-Modulated
24
Peripheral Blood Stem Cell Transplantation
24
Magnetic Resonance Spectroscopy
24
Surgical Procedures, Operative
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
NETWORK
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03683277
2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2
Terminated
26 enrolled